Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE002 (USA) (Dr. Nolan)
· consented 2023-02-17
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: UNKNOWN; onset 2023-07-17 (study day 140); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 154); relationship: N
severe
serious
assessed
2026-08-18
Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-30 (study day 276); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-01-12 (study day 319); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-21 (study day 328); relationship: Y
mild
assessed
2026-08-18
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-01 (study day 339); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.